Glutamatergic Dysbalance and Oxidative Stress in In Vivo and In Vitro Models of Psychosis Based on Chronic NMDA Receptor Antagonism

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Genius, Just ^a,b   Geiger, Johanna ^a   Dölzer, Anna Lena ^a   Benninghoff, Jens ^a,b   Giegling, Ina ^a,c   Hartmann, Annette M ^a   Möller, Hans Jürgen ^a   Rujescu, Dan ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; DIZOCILPINE; GLUTAMIC ACID; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE MODEL; EMBRYO; EMBRYO CELL; GLUTAMATE METABOLISM; GLUTAMATERGIC SYSTEM; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLISM; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PSYCHOSIS; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELLS, CULTURED; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HALOPERIDOL; HIPPOCAMPUS; MALE; OXIDATIVE STRESS; RATS; RATS, LONG-EVANS; REACTIVE OXYGEN SPECIES; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TYROSINE;

EID: 84880275846     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059395     Document Type: Article

References (61)

1. Abel KM, Allin MP, Hemsley DR, Geyer MA (2003) Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44, 729-737.
2. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, et al. (1994) Arch. Gen. Psychiatry 51, 199-214.
3. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9-19.
4. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25, 455-467.
5. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, et al. (1997) Neuropsychopharmacology 17, 141-150.
6. Al Amin HA, Shannon WC, Weinberger DR, Lipska BK (2001) Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus. Biol. Psychiatry 49, 528-539.
7. Becker A, Peters B, Schroeder H, Mann T, Huether G, et al. (2003) Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 687-700.
8. Ellison GD, Keys AS (1996) Persisting changes in brain glucose uptake following neurotoxic doses of phencyclidine which mirror the acute effects of the drug. Psychopharmacology (Berl) 126, 271-274.
9. Eyjolfsson EM, Brenner E, Kondziella D, Sonnewald U (2006) Repeated injection of MK801: an animal model of schizophrenia? Neurochem. Int. 48, 541-546.
10. Lipska BK, Lerman DN, Khaing ZZ, Weickert CS, Weinberger DR (2003) Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. Eur. J. Neurosci. 18, 391-402.
11. Morita T, Sonoda R, Nakato K, Koshiya K, Wanibuchi F, et al. (2000) Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus. Psychopharmacology (Berl) 148, 281-288.
12. Sams-Dodd F (1996) Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 7, 3-23.
13. Keilhoff G, Becker A, Grecksch G, Wolf G, Bernstein HG (2004) Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 126, 591-598.
14. Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, et al. (2006) A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry. Apr 15 59(8): 721-9.
15. Braun I, Genius J, Grunze H, Bender A, Möller HJ, et al. (2007) Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr. Res. 97, 254-263.
16. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, et al. (1996) NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci. Mar 15 16(6): 2034-43.
17. Choi DW, Koh JY, Peters S (1988) Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 8, 185-196.
18. Hardingham GE, Bading H (2003) The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 26, 81-89.
19. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, et al. (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science 254, 1515-1518.
20. Smythies J (1999) The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion. Neurotox. Res. 1, 27-39.
21. Nishioka N, Arnold SE (2004) Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry 12, 167-175.
22. Smythies JR (1997) Oxidative reactions and schizophrenia: a review-discussion. Schizophr. Res. 24, 357-364.
23. Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, et al. (2007) Science 318, 1645-1647.
24. Faustman WO, Bardgett M, Faull KF, Pfefferbaum A, Csernansky JG (1999) Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol. Psychiatry 45, 68-75.
25. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, et al. (2005) BMC. Psychiatry 5, 6.
26. van Elst LT, Valerius G, Büchert M, Thiel T, Rüsch N, et al. (2005) Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 58, 724-730.
27. Scarr E, Beneyto M, Meador-Woodruff JH, Deans B (2005) Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology 30, 1521-1531.
28. Paxinos G, Watson CR, Emson PC (1980) AChE-stained horizontal sections of the rat brain in stereotaxic coordinates. J. Neurosci. Methods 3, 129-149.
29. Tsai G, Goff DC, Chang RW, Flood J, Baer L, et al. (1998) Am. J. Psychiatry 155, 1207-1213.
30. Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, et al. (2006) A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry 59, 721-729.
31. Velardo MJ, Simpson VJ, Zahniser NR (1998) Differences in NMDA receptor antagonist-induced locomotor activity and [3H]MK-801 binding sites in short-sleep and long-sleep mice. Alcohol Clin. Exp. Res. 22, 1509-1515.
32. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, et al. (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am. J. Psychiatry 162, 394-396.
33. Tibbo P, Hanstock C, Valiakalayil A, Allen P (2004) 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am. J. Psychiatry 161, 1116-1118.
34. Cabungcal JH, Nicolas D, Kraftsik R, Cuénod M, Do KQ, et al. (2006) Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia. Neurobiol. Dis.
35. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, et al. (2005) Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry 57, 252-260.
36. Zhang ZJ, Reynolds GP (2002) A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr. Res. 55, 1-10.
37. Aizenman E (1995) Modulation of N-methyl-D-aspartate receptors by hydroxyl radicals in rat cortical neurons in vitro. Neurosci. Lett. 189, 57-59.
38. Brimecombe JC, Potthoff WK, Aizenman E (1999) A critical role of the N-methyl-D-aspartate (NMDA) receptor subunit (NR) 2A in the expression of redox sensitivity of NR1/NR2A recombinant NMDA receptors. J. Pharmacol. Exp. Ther. 291, 785-792.
39. Herin GA, Du S, Aizenman E (2001) The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site. J. Neurochem. 78, 1307-1314.
40. Steullet P, Neijt HC, Cuenod M, Do KQ (2006) Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 137, 807-819.
41. van den Berg CJ, Garfinkel D (1971) A stimulation study of brain compartments. Metabolism of glutamate and related substances in mouse brain. Biochem. J. 123, 211-218.
42. Kondziella D, Brenner E, Eyjolfsson EM, Markinhuhta KR, Carlsson ML, et al. (2005) Glial-Neuronal Interactions are Impaired in the Schizophrenia Model of Repeated MK801 Exposure. Neuropsychopharmacology.
43. Krebs MO, Desce JM, Kemel ML, Gauchy C, Godeheu G, et al. (1991) Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J. Neurochem. 56, 81-85.
44. Eyjolfsson EM, Brenner E, Kondziella D, Sonnewald U (2006) Repeated injection of MK801: An animal model of schizophrenia? Neurochem. Int.
45. de Bartolomeis A, Fiore G, Iasevoli F (2005) Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr. Pharm. Des 11, 3561-3594.
46. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A (2005) Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 27 Suppl A, S16-S24.
47. Pietraszek M, Golembiowska K, Bijak M, Ossowska K, Wolfarth S (2002) Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies. Naunyn Schmiedebergs Arch. Pharmacol. 366, 417-424.
48. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921-2927.
49. Leveque JC, Macías W, Rajadhyaksha A, Carlson RR, Barczak A et al. (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 20, 4011-4020.
50. Ossowska K, Pietraszek M, Wardas J, Nowak G, Wolfarth S (1999) Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn Schmiedebergs Arch. Pharmacol. 359, 280-287.
51. Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, et al. (2002) A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 35, 1111-1122.
52. Nieoullon A, Kerkerian L, Dusticier N (1983) Presynaptic dopaminergic control of high affinity glutamate uptake in the striatum. Neurosci. Lett. 43, 191-196.
53. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, et al. (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52, 829-836.
54. Feinberg I, Campbell IG (1998) Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia. Neuroreport 9, 2189-2193.
55. Feifel D, Priebe K (1999) The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating. Psychopharmacology (Berl) 146, 175-179.
56. Akyol O, Herken H, Uz E, Fadillioǧlu E, Unal S, et al. (2002) The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 995-1005.
57. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, et al. (2004) Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 49, 205-209.
58. Goff DC (2005) Pharmacologic implications of neurobiological models of schizophrenia. Harv. Rev. Psychiatry 13, 352-359.
59. Mahadik SP. Scheffer RE (1996) Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 55, 45-54.
60. Coyle JT, Tsai G, Goff DC (2002) Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets. CNS. Neurol. Disord. 1, 183-189.
61. Genius J, Giegling I, Benninghoff J, Rujescu D (2012) Disturbed function of GABAergic interneurons in schizophrenia: Relevance for medical treatment? Curr Pharm Biotechnol. 2012 Jan 26. [Epub ahead of print].